1. Home
  2. AAME vs GANX Comparison

AAME vs GANX Comparison

Compare AAME & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlantic American Corporation

AAME

Atlantic American Corporation

HOLD

Current Price

$2.42

Market Cap

50.6M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$3.90

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AAME
GANX
Founded
1968
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.6M
159.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AAME
GANX
Price
$2.42
$3.90
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
25.5K
1.2M
Earning Date
11-14-2025
11-12-2025
Dividend Yield
0.80%
N/A
EPS Growth
N/A
N/A
EPS
0.23
N/A
Revenue
$208,218,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.91
N/A
Revenue Growth
11.99
N/A
52 Week Low
$1.25
$1.41
52 Week High
$3.71
$4.34

Technical Indicators

Market Signals
Indicator
AAME
GANX
Relative Strength Index (RSI) 47.21 67.19
Support Level $2.34 $3.94
Resistance Level $2.62 $4.34
Average True Range (ATR) 0.15 0.39
MACD 0.02 0.02
Stochastic Oscillator 61.21 71.00

Price Performance

Historical Comparison
AAME
GANX

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: